Daily Cosmetic Research Analysis
Three impactful studies in cosmetic and aesthetic medicine stood out today: a Phase 3 randomized, double-blind trial showed durable, natural-appearing improvements with a ready-to-use liquid botulinum toxin A for glabellar lines; a large case-control study linked higher personal care product exposure patterns to increased prostate cancer odds; and a 650-case series reported real-world outcomes and complications of forehead reduction surgery across a multiracial population.
Summary
Three impactful studies in cosmetic and aesthetic medicine stood out today: a Phase 3 randomized, double-blind trial showed durable, natural-appearing improvements with a ready-to-use liquid botulinum toxin A for glabellar lines; a large case-control study linked higher personal care product exposure patterns to increased prostate cancer odds; and a 650-case series reported real-world outcomes and complications of forehead reduction surgery across a multiracial population.
Research Themes
- Aesthetic neuromodulators and patient-reported outcomes
- Personal care product exposure and cancer epidemiology
- Craniofacial aesthetic surgery outcomes and safety
Selected Articles
1. Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.
In a 6-month, double-blind, multicenter Phase 3 trial, a ready-to-use liquid botulinum toxin A achieved markedly higher patient-reported responder rates for glabellar line improvement versus placebo, with benefits sustained to Month 6. Patients reported natural-looking results, higher satisfaction, and improved psychological well-being.
Impact: Provides high-quality randomized evidence for a novel, ready-to-use neuromodulator with durable and natural-appearing outcomes, likely affecting product adoption and patient counseling.
Clinical Implications: Supports the clinical use of ready-to-use liquid botulinum toxin A for moderate-to-severe glabellar lines, highlighting high satisfaction and natural appearance over 6 months; head-to-head comparisons with existing toxins would further guide choice.
Key Findings
- Responder rates (GL-SLA ≥1-grade improvement) with relaBoNT-A were 97.2% (Day 7), 97.7% (Month 1), 90.0% (Month 3), and 71.0% (Month 6) vs 18.9%, 26.8%, 27.5%, and 22.4% with placebo (P < .001).
- GAIS responder rates were 74.3%–98.1% with relaBoNT-A vs 9.0%–16.2% with placebo.
- Posttreatment FLTSQ scores were higher with relaBoNT-A (Appearance ≥62.5; Treatment Satisfaction ≥83.0) than placebo (≤49.8 and ≤36.8, respectively).
- Patients reported natural-looking results (≥83.3%) and greater confidence (≥75.7%), with FACE-Q well-being improvements (mean +11.0–13.7 vs +0.6–4.5 with placebo).
Methodological Strengths
- Randomized, double-blind, multicenter Phase 3 design
- Use of multiple validated patient-reported outcome instruments (GL-SLA, GAIS, FLTSQ, FACE-Q)
Limitations
- No head-to-head comparison with other botulinum toxin A formulations
- Focus on patient-reported outcomes; detailed objective measures and long-term durability beyond 6 months not reported
Future Directions: Conduct head-to-head RCTs versus established toxins, assess duration beyond 6–9 months, immunogenicity, and real-world effectiveness across skin types and ages.
BACKGROUND: RelabotulinumtoxinA (relaBoNT-A; Relfydess, Galderma, Uppsala, Sweden) is a novel, ready-to-use liquid form of botulinum toxin A, created using PEARL technology to produce a highly effective, complex-free formulation. OBJECTIVES: This study reports the patient-assessed effectiveness and satisfaction outcomes from the relaBoNT-A Phase 3 READY-1 study. METHODS: Adults with moderate-to-severe glabellar lines were randomized 3:1 to receive relaBoNT-A (50 U) or placebo in a 6-month, double-blind, multicenter study. Patient-reported endpoints at maximum frown included ≥1 grade improvement on the glabellar line subject live assessment (GL-SLA) scale from baseline and Global Aesthetic Improvement Scale (GAIS) score. Satisfaction and well-being investigations used the Facial Lines Treatment Satisfaction Questionnaire (FLTSQ), Natural Expressions Questionnaire, and FACE-Q Psychological Function Questionnaire. RESULTS: Overall, 233 adults received relaBoNT-A and 74 received placebo. RelaBoNT-A responder rates for ≥1-grade GL-SLA improvement from baseline at Day 7 and Months 1, 3, and 6 were 97.2%, 97.7%, 90.0%, and 71.0%, respectively, vs 18.9%, 26.8%, 27.5%, and 22.4% with placebo (P < .001). GAIS responder rates were 74.3% to 98.1% (relaBoNT-A) and 9.0% to 16.2% (placebo). Posttreatment FLTSQ Rasch-transformed scores were higher with relaBoNT-A (≥62.5) than placebo (≤49.8) for the Appearance Module and Treatment Satisfaction Module (relaBoNT-A: ≥83.0; placebo: ≤36.8). RelaBoNT-A-treated patients reported looking natural (≥83.3%) and feeling confident when making facial expressions (≥75.7%). Mean change in FACE-Q well-being score was higher with relaBoNT-A (11.0-13.7) vs placebo (0.6-4.5). CONCLUSIONS: Adults with moderate-to-severe glabellar lines receiving a single relaBoNT-A treatment reported significant improvements in glabellar line severity throughout the 6-month study period. RelaBoNT-A provided natural looking results, high satisfaction, and psychological well-being improvements.
2. Personal care products exposure patterns and prostate cancer: evidence from a case-control study in Mexico City.
In 400 cases and 801 controls, high and intermediate personal care product use patterns were associated with higher odds of prostate cancer, and intermediate use correlated with poorly differentiated tumors. Daily perfume use emerged as the most consistently associated individual product.
Impact: Links common personal care product use patterns to prostate cancer risk, highlighting a plausible public health and regulatory concern extending beyond female hormone-sensitive cancers.
Clinical Implications: Clinicians should consider counseling on potential risks of frequent PCP use, especially fragrances, while advocating balanced sun and skin-care practices; findings warrant biomonitoring and product reformulation research.
Key Findings
- High PCP exposure pattern was associated with increased prostate cancer odds (OR 2.6; 95% CI 1.8–3.8) versus low exposure.
- Intermediate PCP exposure pattern showed a modest association with prostate cancer (OR 1.3; 95% CI 1.0–1.8).
- Intermediate exposure was significantly associated with poorly differentiated prostate cancer (OR 1.8; 95% CI 1.1–2.9).
- Daily perfume use was the most consistently associated individual product with prostate cancer risk.
Methodological Strengths
- Relatively large sample with histologically confirmed cases and age-matched controls
- Data-driven exposure patterning via K-means clustering and multivariable adjustment
Limitations
- Self-reported product use prone to recall/misclassification bias; lack of biomarker verification
- Case-control design limits causal inference; potential residual confounding and limited generalizability beyond Mexico City
Future Directions: Prospective cohorts with repeated biospecimens to quantify specific PCP chemicals (e.g., phthalates, parabens, UV filters), exposure–response relationships, and gene–environment interactions; intervention studies on product reformulation.
BACKGROUND: Personal care products (PCPs) use has been associated with a high risk of hormone-sensitive cancers in women. However, this association is poorly understood in hormone-sensitive cancers in men. OBJECTIVE: To investigate the association between PCPs use and prostate cancer (PC) and PC histological differentiation in men from Mexico City. METHODS: We analyzed the information from 400 histologically confirmed incident PC cases and 801 population controls matched by age (±5 y). The usage frequency (daily, weekly, or less, and non-use) of deodorant, body lotion, shampoo, perfume, and shaving or after-shaving products was evaluated based on a structured questionnaire. Using the K-means approach, we selected three patterns according to the usage frequency and number of PCPs used: high, intermediate, and low. Multivariable non-conditional logistic regression models adjusted by selected confounders were conducted to estimate the association between the use of PCPs (patterns, individual products, and number of products used daily) and PC, as well as PC histological differentiation. RESULTS: Compared to the low exposure pattern, the high (OR: 2.6 95% CI: 1.8-3.8) and intermediate (OR: 1.3 95% CI: 1.0-1.8) PCPs patterns were associated with higher odds of PC. Similarly, the intermediate exposure pattern was significantly associated with poorly differentiated PC (OR: 1.8 95% CI: 1.1-2.9). The daily use of perfume was the most consistent PCP associated with PC (OR IMPACT STATEMENT: This study provided evidence that high exposure to personal care products (PCPs) is associated with prostate cancer. Our findings are consistent with those observed regarding hormone-sensitive female cancer and suggest the potential contribution of PCPs to prostatic carcinogenesis.
3. Forehead Reduction Surgery: Outcomes and Complications of 650 Cases in a Multiracial Population.
In 650 forehead reduction surgeries, average forehead shortening was 2.29 cm (28%), with greater advancement in Black patients (2.52 cm). Complication rates were low and scars were generally high quality, though folliculitis and postoperative effluvium were relatively frequent; patient satisfaction was high.
Impact: Provides large-scale, real-world outcomes across a multiracial cohort, informing patient selection, counseling, and risk mitigation in an increasingly popular aesthetic procedure.
Clinical Implications: Set realistic expectations about achievable shortening and temporal hairline limitations; screen for hair/scalp disorders; counsel on common issues like folliculitis and transient effluvium; consider ethnicity-specific risks and scar revision likelihood.
Key Findings
- Average skin excision was 2.29 cm (28% forehead reduction).
- Black ethnicity had greater average advancement (2.52 cm; p < 0.001).
- Complications included dehiscence (n=14), seroma (n=6), necrosis (n=1), folliculitis (n=133), postoperative effluvium (n=98), and alopecia (n=1).
- All scars were rated as good quality; men had fewer effluvium cases (p = 0.016); white ethnicity and >2.3 cm reductions appeared to increase scar revision risk (not statistically confirmed).
Methodological Strengths
- Large sample size (N=650) with diverse ethnic representation
- Systematic capture of complications, scar quality (SCAR scale), and satisfaction
Limitations
- Retrospective design with potential selection and reporting biases
- Not all patients had long-term follow-up; absence of a control group
Future Directions: Prospective, multicenter studies to validate ethnicity-specific outcomes, optimize incision/scar strategies, and develop protocols to reduce folliculitis and effluvium.
BACKGROUND: Forehead reduction surgery (FRS) is gaining popularity as a cosmetic procedure for individuals with disproportionately large foreheads. METHOD: A retrospective review was conducted on patients who underwent FRS from April 2018 to May 2023. Data included sex, age, ethnicity, facial thirds measurement, forehead reduction, dehiscence, hematoma, infection, seroma, and necrosis. Patients with > 12-month follow-up (N = 287) were further analyzed for folliculitis, alopecia, postoperative effluvium, scar quality (SCAR scale) and patient satisfaction (5-point Likert scale). RESULTS: A total of 650 patients (95.5% female) underwent FRS, with an average skin excision of 2.29 cm, representing a 28% forehead reduction. Black ethnicity was associated with greater reductions, with an average advancement of 2.52 cm (p < 0.001). Complications included 14 cases of dehiscence, 6 seromas, 1 necrosis, 133 cases of folliculitis, 98 of postoperative effluvium, and 1 of alopecia. Men had significantly fewer cases of effluvium (p = 0.016). All scars were evaluated as good quality. White ethnicity and reductions exceeding 2.3 cm appeared to increase the risk of scar revision, though not statistically confirmed. CONCLUSIONS: FRS is an effective and safe technique with few complications and high patient satisfaction. It is essential to manage expectations and educate patients on the limitations, particularly regarding forehead shortening, correction of temporal recesses, scar development, and more frequent complications such as folliculitis. Patient selection should focus on capillary diseases that may impact long-term outcomes, such as male pattern baldness and frontal fibrosing alopecia, as well as addressing unrealistic expectations regarding the results. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .